HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating
HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in
adult participants with advanced or metastatic solid tumors known to be expressing PTK7.
The study employs a sequential dose escalation and dose expansion design without a
control group.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07444814.
Locations matching your search criteria
United States
Ohio
Cleveland
Case Comprehensive Cancer CenterStatus: Active
Name Not Available
The study consists of 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion).
In Phase 1a, participants with non-squamous Endothelial Growth Factor Receptor Wild type
(EGFR Wt) NSCLC, platinum resistant ovarian cancer (PROC), and endometrial cancer will be
enrolled. In Phase 1b, non-squamous EGFR Wt NSCLC expansion cohort(s) will be opened,
based on the safety, tolerability, PK, and preliminary antitumor data in Phase 1a.
In Phase 1a of the study, HWK-007 will initially be administered as an intravenous (IV)
infusion every 3 weeks (Q3W).
Lead OrganizationWhitehawk Therapeutics, Inc.
Principal InvestigatorMargaret Dugan
